Global Myasthenia Gravis

Myasthenia Gravis Comprehensive Study by Type (Congenital Hereditary, Autoimmune Disease), Application (Hospital, Medical Clinical Research Center, Others), Treatment type (Therapeutic approach, Medication approach), Diagnostics test types (Edrophonium test, Blood Analysis, Ice Pack test, Others (Repetitive nerve stimulation, others)), Peak Incidence (Male (50’s to 60’s), Female (20’s to 30’s)) Players and Region - Global Market Outlook to 2030

Myasthenia Gravis Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 18.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Myasthenia Gravis
Myasthenia Gravis is an autoimmune disorder affecting the myoneural junction is characterized by varying degrees of weakness of the voluntary muscles. Myasthenia gravis is an autoimmune disorder mainly caused by antibodies to the muscle acetylcholine receptors (AChRs) at the neuromuscular junction. Loss of these receptors leads to a defect in neuromuscular transmission with muscle weakness and fatigue. It is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR18.2%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Myasthenia Gravis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Mitsubishi Tanabe Pharma (United States), Novartis(Switzerland), CSL Behring(United States), Alexion Pharmaceuticals, Catalyst Pharmaceuticals (United States), Valent Pharmaceuticals(United States), Argenx(United States), Grifols Therapeutics (Spain), UCB Pharma (Belgium) and Astellas Pharma(Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Myasthenia Gravis market by Type (Congenital Hereditary and Autoimmune Disease), Application (Hospital, Medical Clinical Research Center and Others) and Region.



On the basis of geography, the market of Myasthenia Gravis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment type, the sub-segment i.e. Therapeutic approach will boost the Myasthenia Gravis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnostics test types, the sub-segment i.e. Edrophonium test will boost the Myasthenia Gravis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Peak Incidence , the sub-segment i.e. Male (50’s to 60’s) will boost the Myasthenia Gravis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising research and development activities

Market Growth Drivers:
Increasing geriatric population

Challenges:
The adverse effect of the Myasthenia Gravis

Restraints:
Unawareness regarding the cause of the Myasthenia Gravis

Opportunities:
Incidence and prevalence of the disorder seem to be rising

Market Leaders and their expansionary development strategies
In December 2020 AstraZeneca United Kingdom Swedish multinational pharmaceutical and biopharmaceutical company Set to Acquire Alexion Pharmaceuticals. The deal is expected to be finalized in the third quarter of 2021. and In February 2021 Horizon acquires Viela, will develop ibalizumab for mg symptoms. In Usd3.05 billion deal, horizon therapeutics will acquire viela bio, the developer of ibalizumab, a potential treatment for autoimmune diseases such as myasthenia gravis (mg).
In February 2019 Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis (gMG) and other rare, tissue-based complement-mediated diseases.
incidence and prevalence of the disorder seem to be rising

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Myasthenia Gravis Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Congenital Hereditary
  • Autoimmune Disease
By Application
  • Hospital
  • Medical Clinical Research Center
  • Others
By Treatment type
  • Therapeutic approach
  • Medication approach

By Diagnostics test types
  • Edrophonium test
  • Blood Analysis
  • Ice Pack test
  • Others (Repetitive nerve stimulation, others)

By Peak Incidence
  • Male (50’s to 60’s)
  • Female (20’s to 30’s)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. The adverse effect of the Myasthenia Gravis
    • 3.4. Market Trends
      • 3.4.1. Rising research and development activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Myasthenia Gravis, by Type, Application, Treatment type, Diagnostics test types, Peak Incidence and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Myasthenia Gravis (Value)
      • 5.2.1. Global Myasthenia Gravis by: Type (Value)
        • 5.2.1.1. Congenital Hereditary
        • 5.2.1.2. Autoimmune Disease
      • 5.2.2. Global Myasthenia Gravis by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Medical Clinical Research Center
        • 5.2.2.3. Others
      • 5.2.3. Global Myasthenia Gravis by: Treatment type (Value)
        • 5.2.3.1. Therapeutic approach
        • 5.2.3.2. Medication approach
      • 5.2.4. Global Myasthenia Gravis by: Diagnostics test types (Value)
        • 5.2.4.1. Edrophonium test
        • 5.2.4.2. Blood Analysis
        • 5.2.4.3. Ice Pack test
        • 5.2.4.4. Others (Repetitive nerve stimulation, others)
      • 5.2.5. Global Myasthenia Gravis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Myasthenia Gravis (Volume)
      • 5.3.1. Global Myasthenia Gravis by: Type (Volume)
        • 5.3.1.1. Congenital Hereditary
        • 5.3.1.2. Autoimmune Disease
      • 5.3.2. Global Myasthenia Gravis by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Medical Clinical Research Center
        • 5.3.2.3. Others
      • 5.3.3. Global Myasthenia Gravis by: Treatment type (Volume)
        • 5.3.3.1. Therapeutic approach
        • 5.3.3.2. Medication approach
      • 5.3.4. Global Myasthenia Gravis by: Diagnostics test types (Volume)
        • 5.3.4.1. Edrophonium test
        • 5.3.4.2. Blood Analysis
        • 5.3.4.3. Ice Pack test
        • 5.3.4.4. Others (Repetitive nerve stimulation, others)
      • 5.3.5. Global Myasthenia Gravis Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Myasthenia Gravis (Price)
      • 5.4.1. Global Myasthenia Gravis by: Type (Price)
  • 6. Myasthenia Gravis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mitsubishi Tanabe Pharma (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis(Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Behring(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alexion Pharmaceuticals
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Catalyst Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Valent Pharmaceuticals(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Argenx(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Grifols Therapeutics (Spain)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UCB Pharma (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Astellas Pharma(Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Myasthenia Gravis Sale, by Type, Application, Treatment type, Diagnostics test types, Peak Incidence and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Myasthenia Gravis (Value)
      • 7.2.1. Global Myasthenia Gravis by: Type (Value)
        • 7.2.1.1. Congenital Hereditary
        • 7.2.1.2. Autoimmune Disease
      • 7.2.2. Global Myasthenia Gravis by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Medical Clinical Research Center
        • 7.2.2.3. Others
      • 7.2.3. Global Myasthenia Gravis by: Treatment type (Value)
        • 7.2.3.1. Therapeutic approach
        • 7.2.3.2. Medication approach
      • 7.2.4. Global Myasthenia Gravis by: Diagnostics test types (Value)
        • 7.2.4.1. Edrophonium test
        • 7.2.4.2. Blood Analysis
        • 7.2.4.3. Ice Pack test
        • 7.2.4.4. Others (Repetitive nerve stimulation, others)
      • 7.2.5. Global Myasthenia Gravis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Myasthenia Gravis (Volume)
      • 7.3.1. Global Myasthenia Gravis by: Type (Volume)
        • 7.3.1.1. Congenital Hereditary
        • 7.3.1.2. Autoimmune Disease
      • 7.3.2. Global Myasthenia Gravis by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Medical Clinical Research Center
        • 7.3.2.3. Others
      • 7.3.3. Global Myasthenia Gravis by: Treatment type (Volume)
        • 7.3.3.1. Therapeutic approach
        • 7.3.3.2. Medication approach
      • 7.3.4. Global Myasthenia Gravis by: Diagnostics test types (Volume)
        • 7.3.4.1. Edrophonium test
        • 7.3.4.2. Blood Analysis
        • 7.3.4.3. Ice Pack test
        • 7.3.4.4. Others (Repetitive nerve stimulation, others)
      • 7.3.5. Global Myasthenia Gravis Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Myasthenia Gravis (Price)
      • 7.4.1. Global Myasthenia Gravis by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Myasthenia Gravis: by Type(USD Million)
  • Table 2. Myasthenia Gravis Congenital Hereditary , by Region USD Million (2018-2023)
  • Table 3. Myasthenia Gravis Autoimmune Disease , by Region USD Million (2018-2023)
  • Table 4. Myasthenia Gravis: by Application(USD Million)
  • Table 5. Myasthenia Gravis Hospital , by Region USD Million (2018-2023)
  • Table 6. Myasthenia Gravis Medical Clinical Research Center , by Region USD Million (2018-2023)
  • Table 7. Myasthenia Gravis Others , by Region USD Million (2018-2023)
  • Table 8. Myasthenia Gravis: by Treatment type(USD Million)
  • Table 9. Myasthenia Gravis Therapeutic approach , by Region USD Million (2018-2023)
  • Table 10. Myasthenia Gravis Medication approach , by Region USD Million (2018-2023)
  • Table 11. Myasthenia Gravis: by Diagnostics test types(USD Million)
  • Table 12. Myasthenia Gravis Edrophonium test , by Region USD Million (2018-2023)
  • Table 13. Myasthenia Gravis Blood Analysis , by Region USD Million (2018-2023)
  • Table 14. Myasthenia Gravis Ice Pack test , by Region USD Million (2018-2023)
  • Table 15. Myasthenia Gravis Others (Repetitive nerve stimulation, others) , by Region USD Million (2018-2023)
  • Table 16. South America Myasthenia Gravis, by Country USD Million (2018-2023)
  • Table 17. South America Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 18. South America Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 19. South America Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 20. South America Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 21. South America Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 22. Brazil Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 23. Brazil Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 24. Brazil Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 25. Brazil Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 26. Brazil Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 27. Argentina Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 28. Argentina Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 29. Argentina Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 30. Argentina Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 31. Argentina Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 32. Rest of South America Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 35. Rest of South America Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 36. Rest of South America Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 37. Asia Pacific Myasthenia Gravis, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 41. Asia Pacific Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 42. Asia Pacific Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 43. China Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 44. China Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 45. China Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 46. China Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 47. China Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 48. Japan Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 49. Japan Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 50. Japan Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 51. Japan Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 52. Japan Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 53. India Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 54. India Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 55. India Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 56. India Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 57. India Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 58. South Korea Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 59. South Korea Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 60. South Korea Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 61. South Korea Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 62. South Korea Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 63. Taiwan Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 64. Taiwan Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 65. Taiwan Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 66. Taiwan Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 67. Taiwan Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 68. Australia Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 69. Australia Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 70. Australia Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 71. Australia Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 72. Australia Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 78. Europe Myasthenia Gravis, by Country USD Million (2018-2023)
  • Table 79. Europe Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 80. Europe Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 81. Europe Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 82. Europe Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 83. Europe Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 84. Germany Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 85. Germany Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 86. Germany Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 87. Germany Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 88. Germany Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 89. France Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 90. France Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 91. France Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 92. France Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 93. France Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 94. Italy Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 95. Italy Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 96. Italy Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 97. Italy Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 98. Italy Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 99. United Kingdom Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 100. United Kingdom Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 101. United Kingdom Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 102. United Kingdom Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 103. United Kingdom Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 104. Netherlands Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 105. Netherlands Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 106. Netherlands Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 107. Netherlands Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 108. Netherlands Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 109. Rest of Europe Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 110. Rest of Europe Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 111. Rest of Europe Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 112. Rest of Europe Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 113. Rest of Europe Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 114. MEA Myasthenia Gravis, by Country USD Million (2018-2023)
  • Table 115. MEA Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 116. MEA Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 117. MEA Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 118. MEA Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 119. MEA Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 120. Middle East Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 121. Middle East Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 122. Middle East Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 123. Middle East Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 124. Middle East Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 125. Africa Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 126. Africa Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 127. Africa Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 128. Africa Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 129. Africa Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 130. North America Myasthenia Gravis, by Country USD Million (2018-2023)
  • Table 131. North America Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 132. North America Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 133. North America Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 134. North America Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 135. North America Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 136. United States Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 137. United States Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 138. United States Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 139. United States Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 140. United States Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 141. Canada Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 142. Canada Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 143. Canada Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 144. Canada Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 145. Canada Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 146. Mexico Myasthenia Gravis, by Type USD Million (2018-2023)
  • Table 147. Mexico Myasthenia Gravis, by Application USD Million (2018-2023)
  • Table 148. Mexico Myasthenia Gravis, by Treatment type USD Million (2018-2023)
  • Table 149. Mexico Myasthenia Gravis, by Diagnostics test types USD Million (2018-2023)
  • Table 150. Mexico Myasthenia Gravis, by Peak Incidence USD Million (2018-2023)
  • Table 151. Myasthenia Gravis Sales: by Type(K Tons)
  • Table 152. Myasthenia Gravis Sales Congenital Hereditary , by Region K Tons (2018-2023)
  • Table 153. Myasthenia Gravis Sales Autoimmune Disease , by Region K Tons (2018-2023)
  • Table 154. Myasthenia Gravis Sales: by Application(K Tons)
  • Table 155. Myasthenia Gravis Sales Hospital , by Region K Tons (2018-2023)
  • Table 156. Myasthenia Gravis Sales Medical Clinical Research Center , by Region K Tons (2018-2023)
  • Table 157. Myasthenia Gravis Sales Others , by Region K Tons (2018-2023)
  • Table 158. Myasthenia Gravis Sales: by Treatment type(K Tons)
  • Table 159. Myasthenia Gravis Sales Therapeutic approach , by Region K Tons (2018-2023)
  • Table 160. Myasthenia Gravis Sales Medication approach , by Region K Tons (2018-2023)
  • Table 161. Myasthenia Gravis Sales: by Diagnostics test types(K Tons)
  • Table 162. Myasthenia Gravis Sales Edrophonium test , by Region K Tons (2018-2023)
  • Table 163. Myasthenia Gravis Sales Blood Analysis , by Region K Tons (2018-2023)
  • Table 164. Myasthenia Gravis Sales Ice Pack test , by Region K Tons (2018-2023)
  • Table 165. Myasthenia Gravis Sales Others (Repetitive nerve stimulation, others) , by Region K Tons (2018-2023)
  • Table 166. South America Myasthenia Gravis Sales, by Country K Tons (2018-2023)
  • Table 167. South America Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 168. South America Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 169. South America Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 170. South America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 171. South America Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 172. Brazil Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 173. Brazil Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 174. Brazil Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 175. Brazil Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 176. Brazil Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 177. Argentina Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 178. Argentina Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 179. Argentina Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 180. Argentina Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 181. Argentina Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 182. Rest of South America Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 183. Rest of South America Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 184. Rest of South America Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 185. Rest of South America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 186. Rest of South America Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 187. Asia Pacific Myasthenia Gravis Sales, by Country K Tons (2018-2023)
  • Table 188. Asia Pacific Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 189. Asia Pacific Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 190. Asia Pacific Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 191. Asia Pacific Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 192. Asia Pacific Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 193. China Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 194. China Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 195. China Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 196. China Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 197. China Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 198. Japan Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 199. Japan Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 200. Japan Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 201. Japan Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 202. Japan Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 203. India Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 204. India Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 205. India Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 206. India Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 207. India Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 208. South Korea Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 209. South Korea Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 210. South Korea Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 211. South Korea Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 212. South Korea Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 213. Taiwan Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 214. Taiwan Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 215. Taiwan Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 216. Taiwan Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 217. Taiwan Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 218. Australia Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 219. Australia Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 220. Australia Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 221. Australia Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 222. Australia Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 223. Rest of Asia-Pacific Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 224. Rest of Asia-Pacific Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 225. Rest of Asia-Pacific Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 226. Rest of Asia-Pacific Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 227. Rest of Asia-Pacific Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 228. Europe Myasthenia Gravis Sales, by Country K Tons (2018-2023)
  • Table 229. Europe Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 230. Europe Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 231. Europe Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 232. Europe Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 233. Europe Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 234. Germany Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 235. Germany Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 236. Germany Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 237. Germany Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 238. Germany Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 239. France Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 240. France Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 241. France Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 242. France Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 243. France Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 244. Italy Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 245. Italy Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 246. Italy Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 247. Italy Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 248. Italy Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 249. United Kingdom Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 250. United Kingdom Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 251. United Kingdom Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 252. United Kingdom Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 253. United Kingdom Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 254. Netherlands Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 255. Netherlands Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 256. Netherlands Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 257. Netherlands Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 258. Netherlands Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 259. Rest of Europe Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 260. Rest of Europe Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 261. Rest of Europe Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 262. Rest of Europe Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 263. Rest of Europe Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 264. MEA Myasthenia Gravis Sales, by Country K Tons (2018-2023)
  • Table 265. MEA Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 266. MEA Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 267. MEA Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 268. MEA Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 269. MEA Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 270. Middle East Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 271. Middle East Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 272. Middle East Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 273. Middle East Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 274. Middle East Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 275. Africa Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 276. Africa Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 277. Africa Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 278. Africa Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 279. Africa Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 280. North America Myasthenia Gravis Sales, by Country K Tons (2018-2023)
  • Table 281. North America Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 282. North America Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 283. North America Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 284. North America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 285. North America Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 286. United States Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 287. United States Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 288. United States Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 289. United States Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 290. United States Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 291. Canada Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 292. Canada Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 293. Canada Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 294. Canada Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 295. Canada Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 296. Mexico Myasthenia Gravis Sales, by Type K Tons (2018-2023)
  • Table 297. Mexico Myasthenia Gravis Sales, by Application K Tons (2018-2023)
  • Table 298. Mexico Myasthenia Gravis Sales, by Treatment type K Tons (2018-2023)
  • Table 299. Mexico Myasthenia Gravis Sales, by Diagnostics test types K Tons (2018-2023)
  • Table 300. Mexico Myasthenia Gravis Sales, by Peak Incidence K Tons (2018-2023)
  • Table 301. Myasthenia Gravis: by Type(USD/Units)
  • Table 302. Company Basic Information, Sales Area and Its Competitors
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Myasthenia Gravis: by Type(USD Million)
  • Table 313. Myasthenia Gravis Congenital Hereditary , by Region USD Million (2025-2030)
  • Table 314. Myasthenia Gravis Autoimmune Disease , by Region USD Million (2025-2030)
  • Table 315. Myasthenia Gravis: by Application(USD Million)
  • Table 316. Myasthenia Gravis Hospital , by Region USD Million (2025-2030)
  • Table 317. Myasthenia Gravis Medical Clinical Research Center , by Region USD Million (2025-2030)
  • Table 318. Myasthenia Gravis Others , by Region USD Million (2025-2030)
  • Table 319. Myasthenia Gravis: by Treatment type(USD Million)
  • Table 320. Myasthenia Gravis Therapeutic approach , by Region USD Million (2025-2030)
  • Table 321. Myasthenia Gravis Medication approach , by Region USD Million (2025-2030)
  • Table 322. Myasthenia Gravis: by Diagnostics test types(USD Million)
  • Table 323. Myasthenia Gravis Edrophonium test , by Region USD Million (2025-2030)
  • Table 324. Myasthenia Gravis Blood Analysis , by Region USD Million (2025-2030)
  • Table 325. Myasthenia Gravis Ice Pack test , by Region USD Million (2025-2030)
  • Table 326. Myasthenia Gravis Others (Repetitive nerve stimulation, others) , by Region USD Million (2025-2030)
  • Table 327. South America Myasthenia Gravis, by Country USD Million (2025-2030)
  • Table 328. South America Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 329. South America Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 330. South America Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 331. South America Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 332. South America Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 333. Brazil Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 334. Brazil Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 335. Brazil Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 336. Brazil Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 337. Brazil Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 338. Argentina Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 339. Argentina Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 340. Argentina Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 341. Argentina Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 342. Argentina Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 343. Rest of South America Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 344. Rest of South America Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 345. Rest of South America Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 346. Rest of South America Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 347. Rest of South America Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 348. Asia Pacific Myasthenia Gravis, by Country USD Million (2025-2030)
  • Table 349. Asia Pacific Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 350. Asia Pacific Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 351. Asia Pacific Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 352. Asia Pacific Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 353. Asia Pacific Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 354. China Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 355. China Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 356. China Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 357. China Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 358. China Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 359. Japan Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 360. Japan Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 361. Japan Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 362. Japan Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 363. Japan Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 364. India Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 365. India Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 366. India Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 367. India Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 368. India Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 369. South Korea Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 370. South Korea Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 371. South Korea Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 372. South Korea Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 373. South Korea Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 374. Taiwan Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 375. Taiwan Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 376. Taiwan Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 377. Taiwan Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 378. Taiwan Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 379. Australia Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 380. Australia Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 381. Australia Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 382. Australia Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 383. Australia Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 384. Rest of Asia-Pacific Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 385. Rest of Asia-Pacific Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 386. Rest of Asia-Pacific Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 387. Rest of Asia-Pacific Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 388. Rest of Asia-Pacific Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 389. Europe Myasthenia Gravis, by Country USD Million (2025-2030)
  • Table 390. Europe Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 391. Europe Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 392. Europe Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 393. Europe Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 394. Europe Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 395. Germany Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 396. Germany Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 397. Germany Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 398. Germany Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 399. Germany Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 400. France Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 401. France Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 402. France Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 403. France Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 404. France Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 405. Italy Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 406. Italy Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 407. Italy Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 408. Italy Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 409. Italy Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 410. United Kingdom Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 411. United Kingdom Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 412. United Kingdom Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 413. United Kingdom Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 414. United Kingdom Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 415. Netherlands Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 416. Netherlands Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 417. Netherlands Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 418. Netherlands Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 419. Netherlands Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 420. Rest of Europe Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 421. Rest of Europe Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 422. Rest of Europe Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 423. Rest of Europe Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 424. Rest of Europe Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 425. MEA Myasthenia Gravis, by Country USD Million (2025-2030)
  • Table 426. MEA Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 427. MEA Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 428. MEA Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 429. MEA Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 430. MEA Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 431. Middle East Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 432. Middle East Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 433. Middle East Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 434. Middle East Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 435. Middle East Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 436. Africa Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 437. Africa Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 438. Africa Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 439. Africa Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 440. Africa Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 441. North America Myasthenia Gravis, by Country USD Million (2025-2030)
  • Table 442. North America Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 443. North America Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 444. North America Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 445. North America Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 446. North America Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 447. United States Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 448. United States Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 449. United States Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 450. United States Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 451. United States Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 452. Canada Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 453. Canada Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 454. Canada Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 455. Canada Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 456. Canada Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 457. Mexico Myasthenia Gravis, by Type USD Million (2025-2030)
  • Table 458. Mexico Myasthenia Gravis, by Application USD Million (2025-2030)
  • Table 459. Mexico Myasthenia Gravis, by Treatment type USD Million (2025-2030)
  • Table 460. Mexico Myasthenia Gravis, by Diagnostics test types USD Million (2025-2030)
  • Table 461. Mexico Myasthenia Gravis, by Peak Incidence USD Million (2025-2030)
  • Table 462. Myasthenia Gravis Sales: by Type(K Tons)
  • Table 463. Myasthenia Gravis Sales Congenital Hereditary , by Region K Tons (2025-2030)
  • Table 464. Myasthenia Gravis Sales Autoimmune Disease , by Region K Tons (2025-2030)
  • Table 465. Myasthenia Gravis Sales: by Application(K Tons)
  • Table 466. Myasthenia Gravis Sales Hospital , by Region K Tons (2025-2030)
  • Table 467. Myasthenia Gravis Sales Medical Clinical Research Center , by Region K Tons (2025-2030)
  • Table 468. Myasthenia Gravis Sales Others , by Region K Tons (2025-2030)
  • Table 469. Myasthenia Gravis Sales: by Treatment type(K Tons)
  • Table 470. Myasthenia Gravis Sales Therapeutic approach , by Region K Tons (2025-2030)
  • Table 471. Myasthenia Gravis Sales Medication approach , by Region K Tons (2025-2030)
  • Table 472. Myasthenia Gravis Sales: by Diagnostics test types(K Tons)
  • Table 473. Myasthenia Gravis Sales Edrophonium test , by Region K Tons (2025-2030)
  • Table 474. Myasthenia Gravis Sales Blood Analysis , by Region K Tons (2025-2030)
  • Table 475. Myasthenia Gravis Sales Ice Pack test , by Region K Tons (2025-2030)
  • Table 476. Myasthenia Gravis Sales Others (Repetitive nerve stimulation, others) , by Region K Tons (2025-2030)
  • Table 477. South America Myasthenia Gravis Sales, by Country K Tons (2025-2030)
  • Table 478. South America Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 479. South America Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 480. South America Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 481. South America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 482. South America Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 483. Brazil Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 484. Brazil Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 485. Brazil Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 486. Brazil Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 487. Brazil Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 488. Argentina Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 489. Argentina Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 490. Argentina Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 491. Argentina Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 492. Argentina Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 493. Rest of South America Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 494. Rest of South America Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 495. Rest of South America Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 496. Rest of South America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 497. Rest of South America Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 498. Asia Pacific Myasthenia Gravis Sales, by Country K Tons (2025-2030)
  • Table 499. Asia Pacific Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 500. Asia Pacific Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 501. Asia Pacific Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 502. Asia Pacific Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 503. Asia Pacific Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 504. China Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 505. China Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 506. China Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 507. China Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 508. China Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 509. Japan Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 510. Japan Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 511. Japan Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 512. Japan Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 513. Japan Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 514. India Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 515. India Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 516. India Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 517. India Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 518. India Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 519. South Korea Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 520. South Korea Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 521. South Korea Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 522. South Korea Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 523. South Korea Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 524. Taiwan Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 525. Taiwan Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 526. Taiwan Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 527. Taiwan Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 528. Taiwan Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 529. Australia Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 530. Australia Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 531. Australia Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 532. Australia Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 533. Australia Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 534. Rest of Asia-Pacific Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 535. Rest of Asia-Pacific Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 536. Rest of Asia-Pacific Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 537. Rest of Asia-Pacific Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 538. Rest of Asia-Pacific Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 539. Europe Myasthenia Gravis Sales, by Country K Tons (2025-2030)
  • Table 540. Europe Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 541. Europe Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 542. Europe Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 543. Europe Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 544. Europe Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 545. Germany Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 546. Germany Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 547. Germany Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 548. Germany Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 549. Germany Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 550. France Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 551. France Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 552. France Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 553. France Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 554. France Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 555. Italy Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 556. Italy Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 557. Italy Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 558. Italy Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 559. Italy Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 560. United Kingdom Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 561. United Kingdom Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 562. United Kingdom Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 563. United Kingdom Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 564. United Kingdom Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 565. Netherlands Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 566. Netherlands Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 567. Netherlands Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 568. Netherlands Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 569. Netherlands Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 570. Rest of Europe Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 571. Rest of Europe Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 572. Rest of Europe Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 573. Rest of Europe Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 574. Rest of Europe Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 575. MEA Myasthenia Gravis Sales, by Country K Tons (2025-2030)
  • Table 576. MEA Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 577. MEA Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 578. MEA Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 579. MEA Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 580. MEA Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 581. Middle East Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 582. Middle East Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 583. Middle East Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 584. Middle East Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 585. Middle East Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 586. Africa Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 587. Africa Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 588. Africa Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 589. Africa Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 590. Africa Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 591. North America Myasthenia Gravis Sales, by Country K Tons (2025-2030)
  • Table 592. North America Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 593. North America Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 594. North America Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 595. North America Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 596. North America Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 597. United States Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 598. United States Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 599. United States Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 600. United States Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 601. United States Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 602. Canada Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 603. Canada Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 604. Canada Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 605. Canada Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 606. Canada Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 607. Mexico Myasthenia Gravis Sales, by Type K Tons (2025-2030)
  • Table 608. Mexico Myasthenia Gravis Sales, by Application K Tons (2025-2030)
  • Table 609. Mexico Myasthenia Gravis Sales, by Treatment type K Tons (2025-2030)
  • Table 610. Mexico Myasthenia Gravis Sales, by Diagnostics test types K Tons (2025-2030)
  • Table 611. Mexico Myasthenia Gravis Sales, by Peak Incidence K Tons (2025-2030)
  • Table 612. Myasthenia Gravis: by Type(USD/Units)
  • Table 613. Research Programs/Design for This Report
  • Table 614. Key Data Information from Secondary Sources
  • Table 615. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Myasthenia Gravis: by Type USD Million (2018-2023)
  • Figure 5. Global Myasthenia Gravis: by Application USD Million (2018-2023)
  • Figure 6. Global Myasthenia Gravis: by Treatment type USD Million (2018-2023)
  • Figure 7. Global Myasthenia Gravis: by Diagnostics test types USD Million (2018-2023)
  • Figure 8. South America Myasthenia Gravis Share (%), by Country
  • Figure 9. Asia Pacific Myasthenia Gravis Share (%), by Country
  • Figure 10. Europe Myasthenia Gravis Share (%), by Country
  • Figure 11. MEA Myasthenia Gravis Share (%), by Country
  • Figure 12. North America Myasthenia Gravis Share (%), by Country
  • Figure 13. Global Myasthenia Gravis: by Type K Tons (2018-2023)
  • Figure 14. Global Myasthenia Gravis: by Application K Tons (2018-2023)
  • Figure 15. Global Myasthenia Gravis: by Treatment type K Tons (2018-2023)
  • Figure 16. Global Myasthenia Gravis: by Diagnostics test types K Tons (2018-2023)
  • Figure 17. South America Myasthenia Gravis Share (%), by Country
  • Figure 18. Asia Pacific Myasthenia Gravis Share (%), by Country
  • Figure 19. Europe Myasthenia Gravis Share (%), by Country
  • Figure 20. MEA Myasthenia Gravis Share (%), by Country
  • Figure 21. North America Myasthenia Gravis Share (%), by Country
  • Figure 22. Global Myasthenia Gravis: by Type USD/Units (2018-2023)
  • Figure 23. Global Myasthenia Gravis share by Players 2023 (%)
  • Figure 24. Global Myasthenia Gravis share by Players (Top 3) 2023(%)
  • Figure 25. Global Myasthenia Gravis share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Mitsubishi Tanabe Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mitsubishi Tanabe Pharma (United States) Revenue: by Geography 2023
  • Figure 29. Novartis(Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis(Switzerland) Revenue: by Geography 2023
  • Figure 31. CSL Behring(United States) Revenue, Net Income and Gross profit
  • Figure 32. CSL Behring(United States) Revenue: by Geography 2023
  • Figure 33. Alexion Pharmaceuticals Revenue, Net Income and Gross profit
  • Figure 34. Alexion Pharmaceuticals Revenue: by Geography 2023
  • Figure 35. Catalyst Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Catalyst Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 37. Valent Pharmaceuticals(United States) Revenue, Net Income and Gross profit
  • Figure 38. Valent Pharmaceuticals(United States) Revenue: by Geography 2023
  • Figure 39. Argenx(United States) Revenue, Net Income and Gross profit
  • Figure 40. Argenx(United States) Revenue: by Geography 2023
  • Figure 41. Grifols Therapeutics (Spain) Revenue, Net Income and Gross profit
  • Figure 42. Grifols Therapeutics (Spain) Revenue: by Geography 2023
  • Figure 43. UCB Pharma (Belgium) Revenue, Net Income and Gross profit
  • Figure 44. UCB Pharma (Belgium) Revenue: by Geography 2023
  • Figure 45. Astellas Pharma(Japan) Revenue, Net Income and Gross profit
  • Figure 46. Astellas Pharma(Japan) Revenue: by Geography 2023
  • Figure 47. Global Myasthenia Gravis: by Type USD Million (2025-2030)
  • Figure 48. Global Myasthenia Gravis: by Application USD Million (2025-2030)
  • Figure 49. Global Myasthenia Gravis: by Treatment type USD Million (2025-2030)
  • Figure 50. Global Myasthenia Gravis: by Diagnostics test types USD Million (2025-2030)
  • Figure 51. South America Myasthenia Gravis Share (%), by Country
  • Figure 52. Asia Pacific Myasthenia Gravis Share (%), by Country
  • Figure 53. Europe Myasthenia Gravis Share (%), by Country
  • Figure 54. MEA Myasthenia Gravis Share (%), by Country
  • Figure 55. North America Myasthenia Gravis Share (%), by Country
  • Figure 56. Global Myasthenia Gravis: by Type K Tons (2025-2030)
  • Figure 57. Global Myasthenia Gravis: by Application K Tons (2025-2030)
  • Figure 58. Global Myasthenia Gravis: by Treatment type K Tons (2025-2030)
  • Figure 59. Global Myasthenia Gravis: by Diagnostics test types K Tons (2025-2030)
  • Figure 60. South America Myasthenia Gravis Share (%), by Country
  • Figure 61. Asia Pacific Myasthenia Gravis Share (%), by Country
  • Figure 62. Europe Myasthenia Gravis Share (%), by Country
  • Figure 63. MEA Myasthenia Gravis Share (%), by Country
  • Figure 64. North America Myasthenia Gravis Share (%), by Country
  • Figure 65. Global Myasthenia Gravis: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Mitsubishi Tanabe Pharma (United States)
  • Novartis(Switzerland)
  • CSL Behring(United States)
  • Alexion Pharmaceuticals
  • Catalyst Pharmaceuticals (United States)
  • Valent Pharmaceuticals(United States)
  • Argenx(United States)
  • Grifols Therapeutics (Spain)
  • UCB Pharma (Belgium)
  • Astellas Pharma(Japan)
Select User Access Type

Key Highlights of Report


Apr 2024 223 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Myasthenia Gravis Quantitative research analysis
Global Myasthenia Gravis Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Mitsubishi Tanabe Pharma (United States), Novartis(Switzerland), CSL Behring(United States), Alexion Pharmaceuticals, Catalyst Pharmaceuticals (United States), Valent Pharmaceuticals(United States), Argenx(United States), Grifols Therapeutics (Spain), UCB Pharma (Belgium) and Astellas Pharma(Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising research and development activities" is seen as one of major influencing trends for Myasthenia Gravis Market during projected period 2023-2030.
The Myasthenia Gravis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Myasthenia Gravis Report?

Have a Query? Click Here

Other Related Reports

Transdermal Skin Patches Comprehensive Study by Type (Drug in Adhesive, Matrix, Reservoir, Vapor, Other), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospital Ph...
$ 3450
Kidney Cancer Drugs Comprehensive Study by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus)...
$ 3650
Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), ...
$ 3750
Plant Sterol Esters Comprehensive Study by Type (Oil, Powder), End Users (Food & Beverages, Dairy Products, Pharmaceutical, Cosmetics) Players and Region - Global Market Outlook to 2026
$ 3500
Companion Diagnostics Comprehensive Study by End-users (Pharma Companies, Reference Laboratories, CRO, Others), Product & Service (Assay kits & Reagents, Software & Services), Technology Type (Polyme...
$ 3750
Vaccines & Vaccination Comprehensive Study by Type (Monovalent Vaccines, Multivalent Vaccines), Application (Pediatrics disease, Adults disease), Route of Administration (Intramuscular and Subcutaneo...
$ 3750